Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D961H in Japanese paediatric patients with gastrointestinal acid-related diseases
jRCT2080222552Phase 3
- Sponsor
- AstraZeneca
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of esomeprazole in gastric ulcer, duodenal ulcer, acute gastric mucosal injury (AGMI) and 4 more (5 arms), sponsored by AstraZeneca. Primary endpoints: Safety of repeated once-daily oral D961H, Pharmacokinetics of D961H and 2 more.
02
Drugs
esomeprazole
03
Conditions
gastric ulcerduodenal ulceracute gastric mucosal injury (AGMI)Non-erosive Gastroesophageal Reflux Disease (NERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on jRCT2080222552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222552.